GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of my TSH moved and I cannot work out whether ACHIEVE is why — 45 comments in the full submission. View in context.
2.7k
c/orforglipron·submitted 1 year ago by u/flair_enthusiast

my TSH moved and I cannot work out whether ACHIEVE is why

Questionbranch of 8 comments

my TSH moved and I cannot work out whether ACHIEVE is why — a position I have arrived at slowly and would like tested. What is actually known, and what is being assumed. Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its…

Read the full submission and all 45 comments →

This branch

8 comments, started 1 year ago
u/incretin_ivyMOD37 points·1 year ago

Standing reminder: unapproved compound, research material is not for human use, and no schedules for other members.

replysharereportpermalink
u/flair_enthusiastOP19 points·1 year ago

Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.

replysharereportpermalink
[deleted]9 points·1 year ago

[deleted]

replysharereportpermalink
u/flair_enthusiastOP4 points·1 year ago

What did the tolerability table look like at that dose?

replysharereportpermalink
u/throwaway_wl20263 points·1 year ago

a non-peptide agonist does not degrade the way a peptide does

replysharereportpermalink
u/meera_sandvik2 points·1 year ago

That is a phase 2 result being quoted as though the programme had reported.

replysharereportpermalink
u/ahmed_okafor7 points·1 year ago

daily dosing changes adherence in both directions

replysharereportpermalink
u/meera_sandvik4 points·1 year ago

Cosigning on daily dosing. It changes the exposure profile and it changes adherence, in both directions.

replysharereportpermalink

← back to the whole thread

About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/orforglipron
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/phase_two_peteu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →